GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » Cash Conversion Cycle

Winston Pharmaceuticals (Winston Pharmaceuticals) Cash Conversion Cycle : 4.61 (As of Mar. 2010)


View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Winston Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2010 was 4.61.
Winston Pharmaceuticals's Days Inventory for the three months ended in Mar. 2010 was 0.
Winston Pharmaceuticals's Days Payable for the three months ended in Mar. 2010 was 0.
Therefore, Winston Pharmaceuticals's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2010 was 4.61.


Winston Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for Winston Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals Cash Conversion Cycle Chart

Winston Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Dec08 Dec09
Cash Conversion Cycle
-876.00 -153.68 - 26.99 4.32

Winston Pharmaceuticals Quarterly Data
Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.37 8.88 10.66 6.73 4.61

Competitive Comparison of Winston Pharmaceuticals's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Winston Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Winston Pharmaceuticals's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Winston Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Winston Pharmaceuticals's Cash Conversion Cycle falls into.



Winston Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Winston Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2009 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=4.32+0-0
=4.32

Winston Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Mar. 2010 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=4.61+0-0
=4.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Winston Pharmaceuticals  (GREY:WPHM) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Winston Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061
Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser 10 percent owner 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver director, officer: Vice President 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg director, officer: Chief Financial Officer 2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel 10 percent owner 4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines